China’s Ally Bridge Group hit the investment world’s radar in 2015 with its audacious move to take CRO WuXi PharmaTech Inc. private. If the firm and its partners can engineer the first fruits of that move with the listing of WuXi’s biologics unit in Hong Kong this year, the question is what will be its next moves to generate outsized returns for its investors.